Evidence map›Paper›PMID 37891494›Full record

ArticleCellular & molecular biology letters2023

N6-methyladenosine-modified oncofetal lncRNA MIR4435-2HG contributed to stemness features of hepatocellular carcinoma cells by regulating rRNA 2'-O methylation.

Yiqing Zhu, Bang Xiao, Meng Liu, Meiting Chen, Ningqi Xia, Haiyan Guo, Jinfeng Huang, Zhiyong Liu, Fang Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular & molecular biology letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. mAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. mCellular and molecular life sciences : CMLS · 2025
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. N6-methyladenosine-modified long non-coding RNAWorld journal of gastroenterology · 2024
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yiqing Zhu *Department of Medical Genetics, Naval Medical University, Shanghai, 200433, China.
Bang Xiao *Department of Medical Genetics, Naval Medical University, Shanghai, 200433, China.
Meng Liu *Department of Medical Genetics, Naval Medical University, Shanghai, 200433, China.
Meiting Chen *Department of Medical Genetics, Naval Medical University, Shanghai, 200433, China.
Ningqi XiaDepartment of Medical Genetics, Naval Medical University, Shanghai, 200433, China.
Haiyan GuoDepartment of Assisted Reproduction, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Center for Specialty Strategy Research of Shanghai Jiao Tong University China Hospital Development Institute, Shanghai, 200011, China.
Jinfeng HuangDepartment of Medical Genetics, Naval Medical University, Shanghai, 200433, China. jfhuang@smmu.edu.cn.
Zhiyong LiuDepartment of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China. chyang@sibs.ac.cn.
Fang WangDepartment of Medical Genetics, Naval Medical University, Shanghai, 200433, China. wfsjz@smmu.edu.cn.
Second Military Medical University · CNShanghai Jiao Tong University · CN

Funding

National Natural Science Foundation of China 81830085National Natural Science Foundation of China 81971337National Natural Science Foundation of China 81972268Natural Science Foundation of Shanghai 22ZR1477000Natural Science Foundation of Shanghai 23ZR1477300Shanghai Municipal Health Commission 20224Y0105
6 · The paper itself

Abstract

backgroundThe unique expression pattern endows oncofetal genes with great value in cancer diagnosis and treatment. However, only a few oncofetal genes are available for clinical use and the underlying mechanisms that drives the fetal-like reprogramming of cancer cells remain largely unknown.

methodsMicroarray assays and bioinformatic analyses were employed to screen for potential oncofetal long non-coding RNAs (lncRNAs) in hepatocellular carcinoma (HCC). The expression levels of MIR4435-2HG, NOP58 ribonucleoprotein (NOP58), insulin like growth factor 2 mRNA binding protein 1 (IGF2BP1) and stem markers were detected by quantitative polymerase chain reaction. The 2'-O-methylation (2'-O-Me) status of rRNA were detected through reverse transcription at low dNTP concentrations followed by PCR. The regulation of MIR4435-2HG by IGF2BP1 was explored by RNA immunoprecipitation (RIP), methylated RIP (MeRIP) and dual-luciferase assays. The interaction between MIR4435-2HG and NOP58 was investigated by RNA Pulldown, RIP and protein stability assays. In vitro and in vivo function assays were performed to detect the roles of MIR4435-2HG/NOP58 in HCC.

resultsMIR4435-2HG was an oncofetal lncRNA associated with poor prognosis in HCC. Functional experiments showed that overexpression of MIR4435-2HG remarkably enhanced the stem-cell properties of HCC cells, promoting tumorigenesis in vitro and in vivo. Mechanically, MIR4435-2HG directly bound NOP58 and IGF2BP1. IGF2BP1 upregulated MIR4435-2HG expression in HCC through N6-methyladenosine (m6A) modification. Moreover, MIR4435-2HG protected NOP58 from degradation, which raised rRNA 2'-O-Me levels and promoted internal ribosome entry site (IRES)-dependent translation of oncogenes.

conclusionsThis study identified an oncofetal lncRNA MIR4435-2HG, characterized the role of MIR4435-2HG/NOP58 in stemness maintenance and proliferation of HCC cells, and confirmed m6A as a 'driver' that reactivated MR4435-2HG expression in HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsRNA, Long NoncodingCell ProliferationGene Expression Regulation, NeoplasticHumansMethylationRNA, Long NoncodingHepatocellular carcinomaN6-methyladenosineOncofetal lncRNArRNA 2′-O-methylationStemness maintenance

Identifiers

PMID37891494
PMCPMC10612268
OpenAlexW4387972121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.